PUBLICATIONS

  1. Zuo-Wei Wang# , Feng-Ming Zou# , Ao-Li Wang# , Jing Yang , Rui Jin , Bei-Lei Wang , Li-Juan Shen , Shuang Qi , Juan Liu , Jing Liu* , Wen-Chao Wang *, Qing-Song Liu*, Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1. Acta Pharmacol Sin, 2022 Oct 10;doi: 10.1038/s41401-022-00993-5.
  2. Xiaofei Liang#, Chun Wang#, Beilei Wang#, Juan Liu, Shuang Qi, Aoli Wang Qingwang Liu, Maoqing Deng, Li Wang, Jing Liu*,Qingsong Liu*, Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors. European Journal of Medicinal Chemistry, 2022 Sep 21;doi: 10.1016/j.ejmech.2022.114782.
  3. Yun Wu#, Ziping Qi#, Beilei Wang#, Junjie Wang#, Qingwang Liu, Aoli Wang, Chenliang Shi, Bin Zhou, Qianmao Liang, Wenliang Wang, Fengming Zou, Shuang Qi, Zuowei Wang, Li Wang, Wenchao Wang, Jing Liu*, Qingsong Liu*, Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes. J. Med. Chem., 2022 Aug 29; 65, 17, 11818–11839;doi: 10.1021/acs.jmedchem.2c00926.
  4. Chen Hu, Jing Yang, Ziping Qi, Hong Wu, Beilei Wang, Fengming Zou, Husheng Mei, Jing Liu, Wenchao Wang*, Qingsong Liu*, Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities. MedComm, 2022 Aug 2;doi: 10.1002/mco2.161.
  5. Huamin Liang#, Fengming Zou#, Liyi Fu, Qingwang Liu, Beilei Wang, Xiaofei Liang, Jing Liu*, Qing-Song Liu*, PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML). Pharmaceutics., 2022 Aug 10;doi: 10.3390/pharmaceutics14081662.
  6. Chuan-Dong Cheng, Cheng Chen, Li Wang, Yong-Fei Dong, Yang Yang, Yi-Nan Chen, Wan-Xiang Niu, Wen-Chao Wang*, Qing-Song Liu*, Chao-Shi Niu*, Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations. Anal Cell Pathol., 2022 Jun 15;doi: 10.1155/2022/2376288.
  7. Jiang-Yan Cao # , Shuang Qi # , Hong Wu # , Ao-Li Wang , Qing-Wang Liu, Xi-Xiang Li, Bei-Lei Wang, Juan Ge, Feng-Ming Zou, Cheng Chen , Jun-Jie Wang, Chen Hu, Jing Liu*, Wen-Chao Wang*, Qing-Song Liu*, CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers. Acta Pharmacol Sin., 2022 Feb 28;doi: 10.1038/s41401-022-00882-x.
  8. Juan Liu#, Jingjing Gao#, Aoli Wang#, Zongru Jiang#, Shuang Qi, Ziping Qi, Feiyang Liu, Kailin Yu, Jiangyan Cao, Cheng Chen, Chen Hu, Hong Wu , Li Wang , Wenchao Wang, Qingsong Liu*, Jing Liu*, Nintedanib overcomes drug resistance from upregulation of FGFR signaling and imatinib-induced KIT mutations in gastrointestinal stromal tumors. Mol. Oncol., 2022 Feb 23;doi: 10.1002/1878-0261.13199.
  9. Jing Yang #, Ellen L Weisberg # , Shuang Qi # , Wei Ni , Husheng Mei, Zuowei Wang, Chengcheng Meng, Shengzhe Zhang, Mingqi Hou, Ziping Qi, Aoli Wang, Yunyun Jiang, Zongru Jiang, Tao Huang, Qingwang Liu, Robert S Magin, Laura Doherty , Wenchao Wang Jing Liu, Sara J Buhrlage*, Qingsong Liu*, James D Griffin*. Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia, 2022 Jan 17;doi: 10.1038/s41375-021-01494-w.
  10. Beilei Wang# , Hong Wu , Chen Hu , Haizhen Wang , Jing Liu , Wenchao Wang, Qingsong Liu*. An overview of kinase downregulators and recent advances in discovery approaches. Signal Transduct Target Ther., 2021 Dec 20;6(1):423;doi: 10.1038/s41392-021-00826-7.
  11. Bin Zhou#, Xiaofei Liang# , Husheng Mei#, Shuang Qi#, Zongru Jiang, Aoli Wang, Fengming Zou, Qingwang Liu, Juan Liu, Wenliang Wang, Chen Hu, Yongfei Chen, Zuowei Wang, Beilei Wang, Li Wang, Jing Liu*, and Qingsong Liu*. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. J. Med.Chem., 2021 Oct 19.;doi: 10.1021/acs.jmedchem.1c01154.
  12. Chen Hu #, Fengming Zou #, Aoli Wang #, Weili Miao, Qianmao Liang, Ellen L Weisberg, Yinsheng Wang, Jing Liu*, Wenchao Wang*, Qingsong Liu*. Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia. Signal Transduct Target Ther., 2021 Sep 15;6(1):334;doi: 10.1038/s41392-021-00672-7.
  13. Huamin Liang#, Fengming Zou#, Qingwang Liu#, Beilei Wang#, Liyi Fu , Xiaofei Liang, Jing Liu*, Qingsong Liu*. Nanocrystal-loaded liposome for targeted delivery of poorly water-soluble antitumor drugs with high drug loading and stability towards efficient cancer therapy. Int J Pharm., 2021 Feb 26;120418., doi: 10.1016/j.ijpharm.2021.120418.
  14. Tingting Lu#, Jiangyan Cao #, Fengming Zou #, Xixiang Li , Aoli Wang , Wenliang Wang , Huamin Liang , Qingwang Liu , Chen Hu , Cheng Chen , Zhenquan Hu , Wenchao Wang , Lili Li , Jian Ge , Yang Shen , Tao Ren , Jing Liu , Ruixiang Xia*, Qingsong Liu*. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Eur J Pharmacol., 2021 Feb 10;173944., doi: 10.1016/j.ejphar.2021.173944.
  15. Lei Zhu #, Hongxin Zhao #, Juanjuan Liu #, Hao Cai , Bo Wu , Zhijun Liu , Shu Zhou , Qingsong Liu , Xiaokun Li, Bin Bao , Jian Liu , Han Dai*. Dynamic folding modulation generates FGF21 variant against diabetes. EMBO Rep., 2020 Dec9;e51352 , doi: 10.15252/embr.202051352.
  16. Fan Song#, Zhen Qi#, Chen Cheng#, Wang Wenjun#, Wu Qibing#, Ma Huihui, Zhang Chengyuan, Zhang Li, Lu Baojing, Ge Huiyao, Yong Liang, Li Bao, Yu Yafen, Chen Weiwei, Mao Yiwen, Qu Guangbo, Su Li, Wang Aoli, Ding Zhen, Li Haiwen, Zhang Jin, Wang Yonglian, Gao Yufeng, Xu Xihai, Zhu Zhongming, Chen Jun, Zhang Long, Liang Hongqiang, Wu Song, Huang Meng, Xia Quan, Li Ping, Sun Yehuan, Liang Chaozhao, Wei Wei*, Liu Qingsong*, Sun Liangdan*. Clinical efficacy of low-dose emetine for patients with COVID-19 a real-world study. Journal of Bio-X Research, 2020 Dec , doi: 10.1097/JBR.0000000000000076.
  17. Aoli Wang#, Yong Sun#, Qingwang Liu#, Hong Wu#, Juan Liu#, Jun He, Junling Yu, Qing Qing Chen, Yinglu Ge, Zhuhui Zhang, Chen Hu, Cheng Chen, Ziping Q, Fengming Zou, Feiyang Liu, Jie Hu, Ming Zhao, Tao Huang, Beilei Wang, Li Wang, Wei Wang, Wenchao Wang, Tao Ren, Jing Liu, Yehuan Sun, Song Fan, Qibing Wu, Chaozhao Liang, Liangdan Sun*, Bin Su*, Wei Wei* and Qingsong Liu*. Low dose of emetine as potential antiSARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences. Molecular Biomedicine, 2020 Dec , doi: 10.1186/s43556-020-00018-9.
  18. Feng Li#, Xiaofei Liang#, Zongru Jiang#, Aoli Wang#, Junjie Wang, Cheng Chen, Wenliang Wang, Fengming Zou, Ziping Qi, Qingwang Liu, Zhenquan Hu, Jiangyan Cao, Hong Wu, Beilei Wang, Li Wang, Jing Liu*, and Qingsong Liu*. Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. J. Med.Chem. 2020 Nov 12 , doi: 10.1021/acs.jmedchem.0c01544.
  19. Zi Ye #, Yankun Wang #, Hong Wu #, Tong Song , Xixiang Li , Qingsong Liu *, Chu Wang *. Chemoproteomic profiling of an Ibrutinib analogue reveals its unexpected role in DNA damage repair. Chembiochem, 2020 Sep 26 , doi: 10.1002/cbic.202000527.
  20. Juan Liu#, Qianmao Liang#, Aoli Wang#, Fengming Zou#, Ziping Qi, Kailin Yu, Qingwang Liu, Cheng Chen, Jing Liu*, Qingsong Liu*. Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma. Signal Transduction and Targeted Therapy, 2020 Sep 14;5(1):200 , doi: 10.1038/s41392-020-00309-1.
  21. Beilei Wang#, Wentao Zhang#, Xuesong Liu#, Fengming Zou#, Junjie Wang, Qingwang Liu, Aoli Wang, Zhenquan Hu, Yongfei Chen, Shuang Qi, Zongru Jiang, Cheng Chen, Chen Hu, Li Wang, Wenchao Wang, Qingsong Liu*, Jing Liu*. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a Novel Orally Available Type II TRK Kinase Inhibitor Capable of Overcoming Multiple Resistant Mutants. Eur. J. Med. Chem. , Available online 30 Auguest 2020 , doi: 10.1016/j.ejmech.2020.112744.
  22. Liyi Fu #, Fengming Zou #, Qingwang Liu , Beilei Wang , Junqing Wang , Huamin Liang , Xiaofei Liang , Jing Liu , Jinjun Shi *, Qingsong Liu* . An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia. Nanomedicine , 2020 Aug 7;102283 , doi: 10.1016/j.nano.2020.102283.
  23. Ellen Weisberg#*, Alexander Parent , Priscilla L Yang , Martin Sattler , QingsongLiu , Qingwang Liu , Jinhua Wang , Chengcheng Meng , Sara J Buhrlage , Nathanael Gray , James D Griffin. Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res. , 2020 Aug 10;37(9):167, doi: 10.1007/s11095-020-02851-7.
  24. Wen-Liang Wang#, Zong-Ru Jiang#, Chen Hu , Cheng Chen , Zhen-Quan Hu, Ao-Li Wang , Li Wang , Jing Liu*, Wen-Chao Wang*, Qing-Song Liu* . Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52. Acta Pharmacologica Sinica , 2020 Jul 31, doi: 10.1038/s41401-020-0465-8.
  25. Cheng Chen#, Chuan-dong Cheng#, Hong Wu#, Zuo-wei Wang#, Li Wang, Zong-ru Jiang, Ao-li Wang, Chen Hu, Yong-fei Dong, Wan-xiang Niu, Shuang Qi, Zi-ping Qi, Jing Liu, Wen-chao Wang*, Chao-shi Niu* ,Qing-song Liu* . Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. Acta Pharmacologica Sinica , 2020 May 12, doi: 10.1038/s41401-020-0418-2.
  26. Cheng Chen#, Li Wang#, Lili Li#, Aoli Wang, Tao Huang, Jie Hu, Ming Zhao, Feiyang Liu, Shuang Qi, Chen Hu, Wenliang Wang, Jing Liu, Jian Ge, Ruixiang Xia*, Wenchao Wang*, Qingsong Liu* . Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. Experimental Cell Research , 2020 May 3, doi: 10.1016/j.yexcr.2020.112054.
  27. Aoli Wang#, Chen Hu#, Cheng Chen#, Xiaofei Liang#, Beilei Wang#, Fengming Zou, Kailin Yu, Feng Li, Qingwang Liu, Ziping Qi, Junjie Wang, Wenliang Wang, Li Wang, Ellen L. Weisberg, Wenchao Wang, Lili Li, Jian Ge, Ruixiang Xia, Jing Liu*, Qingsong Liu* . Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia. Haematologica , 2020 Apr 16. pii: haematol., doi: 10.3324/haematol.2019.244186.
  28. Wenliang Wang#, Zongru Jiang#, Li Wang#, Aoli Wang#, Juan Liu, Cheng Chen, Kailin Yu, Fengming Zou, Wenchao Wang*, Jing Liu*, Qingsong Liu*. All-Trans Retinoic Acid Exerts Selective Anti-FLT3-ITD Acute myeloid leukemia Efficacy through Downregulating Chk1 Kinase. Cancer Letters , Available online 2 January 2020, doi: 10.1016/j.canlet.2019.12.045.
  29. Xiaofei Liang#, Zongru Jiang#, Zhenghui Huang#, Feng Li#, Cheng Chen, Chen Hu, Wenliang Wang, Zhenquan Hu, Qingwang Liu, Beilei Wang, Li Wang, Ziping Qi, Jing Liu*, Lubin Jiang*, Qingsong Liu*.Discovery of 6′-chloro-N-methyl-5'-(phenylsulfonamido)-[3,3′-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium. European Journal of Medicinal Chemistry , Available online 27 December 2019, doi: 10.1016/j.ejmech.2019.112012.
  30. Li Wang#, Chen Hu#, Aoli Wang#, Cheng Chen#, Jiaxin Wu#, Zongru Jiang, Fengming Zou, Kailin Yu, Hong Wu, Juan Liu, Wenliang Wang, Zuowei Wang, Beilei Wang, Ziping Qi, Qingwang Liu, Wenchao Wang, Lili Li, Jian Ge*Jing Liu* , Qingsong Liu*.Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models. Invest New Drugs , 2019 Dec 23, doi: 10.1007/s10637-019-00868-3.
  31. Sameer S.Chopra, Anne Jenney, Adam Palmer, MarioNiepel, MirraChung, CaitlinMills, Sindhu Carmen, Sivakumaren, QingsongLiu, Jia-YunChen, ClarenceYapp, John M.Asara, Nathanael S.Gray, Peter K.Sorger.Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. Cell Syst. , 2019 Dec 2. pii: S2405-4712(19)30387-4. doi: 10.1016/j.cels.2019.11.001.
  32. Zongru Jiang #, Li Wang#, Xuesong Liu#, Cheng Chen#, Beilei Wang, Wenliang Wang, Chen Hu, Kailin Yu, Ziping Qi, Qingwang Liu, Aoli Wang, Jing Liu, Guangchen Hong*, Wenchao Wang*, Qingsong Liu*. Discovery of a Highly Selective VEGFR2 Kinase Inhibitor CHMFL-VEGFR2-002 as a Novel Anti-angiogenesis Agent. Acta Pharmaceutica Sinica B, 2019, doi: 10.1016/j.apsb.2019.10.004.
  33. Yun Wu#, Beilei Wang#, Junjie Wang#, Shuang Qi#, Fengming Zou, Ziping Qi, Feiyang Liu, Qingwang Liu, Cheng Chen, Chen Hu, Zhenquan Hu, Aoli Wang, Li Wang, Wenchao Wang, Tao Ren, Yujiao Cai, Mingfeng Bai, Qingsong Liu*, Jing Liu*. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. J. Med. Chem. 2019, Jun 28. doi: 10.1021/acs.jmedchem.9b00280
  34. Feiyang Liu#, Fengming Zou#, Cheng Chen#, Kailin Yu#, Xiaochuan Liu, Shuang Qi, Jiaxin Wu, Chen Hu, Zhenquan Hu, Juan Liu, Xuesong Liu, Li Wang, Juan Ge, Wenchao Wang, Tao Ren, Mingfeng Bai, Yujiao Cai, Xudong Xiao, Feng Qian, Jun Tang*, Qingsong Liu*, Jing Liu*. Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors. Ther Adv Med Oncol. First Published May 17, 2019 Research Article, doi: 10.1177/1758835919849757
  35. Xuesong Liu#, Beilei Wang#, Cheng Chen#, Ziping Qi#, Fengming Zou, Junjie Wang, Chen Hu, Aoli Wang, Juan Ge, Qingwang Liu, Kailin Yu, Zhenquan Hu, Zongru Jiang, Wei Wang, Li Wang, Wenchao Wang, Tao Ren, Mingfeng Bai, Qingsong Liu*, and Jing Liu*. Discovery of (E)-N1-(3-fluorophenyl)-N3-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). J. Med.Chem. Publication Date (Web): May 2, 2019 (Article), doi: 10.1021/acs.jmedchem.9b00176
  36. Qi Wang#, Zhenquan Hu, Xiangchao Luo, Jing Liu , Guoqiang Li*, Shugeng Cao* , and Qingsong Liu*. Clavukoellians A–F, Highly Rearranged Nardosinane Sesquiterpenoids with Antiangiogenic Activity from Clavularia koellikeri. J. Nat. Prod. April 17, 2019, doi: 10.1021/acs.jnatprod.9b00100.
  37. Shun Li#, Ying Song, Christine Quach, Hongrui Guo, Gyu-Beom Jang, Hadi Maazi, Shihui Zhao, Nathaniel A. Sands, Qingsong Liu, Gino K. In, David Peng, Weiming Yuan, Keigo Machida, Min Yu, Omid Akbari, Ashley Hagiya, Yongfei Yang, Vasu Punj, Liling Tang* & Chengyu Liang* . Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun. 2019 Apr 12;10(1):1693. doi: 10.1038/s41467-019-09634-8.
  38. Lei Gao#, Yong Hu, Yahui Tian, Zhenzhen Fan, Kun Wang, Hongdan Li, Qian Zhou, Guandi Zeng, Xin Hu, Lei Yu, Shiyu Zhou, Xinyuan Tong, Hsinyi Huang, Haiquan Chen, Qingsong Liu, Wanting Liu, Gong Zhang, Musheng Zeng, Guangbiao Zhou, Qingyu He*, Hongbin Ji* & Liang Chen* . Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition. Nat Commun. 2019 Apr 10;10(1):1665. doi: 10.1038/s41467-019-09295-7.
  39. Jiaxin Wu#, Aoli Wang#, Xixiang Li#, Cheng Chen#, Ziping Qi#, Chen Hu, Wenliang Wang, Hong Wu, Tao Huang, Ming Zhao, Wenchao Wang, Zhenquan Hu, Qingwang Liu, Beilei Wang, Li Wang, Lili Li, Jian Ge, Tao Ren, Ruixiang Xia*, Jing Liu* & Qingsong Liu*. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML). Cancer Biol Ther. 2019 Mar 20:1-9; doi: 10.1080/15384047.2019.1579958. [Epub ahead of print].
  40. Rui-Yuan Pan#, Jun Ma, Xiang-Xi Kong, Xiao-Feng Wang, Shuo-Shuo Li, Xiao-Long Qi, Yu-Han Yan, Jinbo Cheng, Qingsong Liu, Wanzhu Jin, Chang-Heng Tan and Zengqiang Yuan*.Sodium rutin ameliorates Alzheimer's disease-like pathology by enhancing microglial amyloid-β clearance. Sci Adv. 2019 Feb; 5(2): eaau6328. doi: 10.1126/sciadv.aau6328.
  41. Tingting Lu#, Cheng Chen#, Aoli Wang#, Zongru Jiang#, Ziping Qi, Zhenquan Hu, Chen Hu, Feiyang Liu, Wenliang Wang, Hong Wu, Beilei Wang, Li Wang, Shuang Qi, Jiaxin Wu, Wenchao Wang, Jun Tang, Hezhong Yan, Mingfeng Bai, Qingsong Liu*, Jing Liu*. Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models. Cancer Lett. 2019, Jan 23. pii: S0304-3835(19)30044-8. doi: 10.1016/j.canlet.2019.01.024.
  42. Chunshun Li# , Ariel M. Sarotti , Xiaohua Wu , Baojun Yang , James Turkson , Yongfei Chen , Qingsong Liu and Shugeng Cao*. An Unusual Benzoisoquinoline-9-one Derivative and Other Related Compounds with Antiproliferative Activity from Hawaiian Endophytic Fungus Peyronellaea sp. FT431. Molecules. 2019, 24(1), 196; doi: 10.3390/molecules24010196
  43. Xiaofei Liang#, Beilei Wang#, Cheng Chen#, Aoli Wang#, Chen Hu, Fengming Zou, Kailin Yu, Qingwang Liu, Feng Li, Zhenquan Hu, Tingting Lu, Junjie Wang, Li Wang, Ellen Weisberg, Lili Li, Ruixiang Xia, Wenchao Wang, Tao Ren, Jian Ge*, Jing Liu*, and Qingsong Liu*. Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent Fms-like Tyrosine Kinase 3 Internal Tandem Duplications (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. J. Med. Chem. Publication Date (Web): December 19, 2018 (Article), doi: 10.1021/acs.jmedchem.8b01594
  44. Qi Wang#, Zhenquan Hu, Xixiang Li, Aoli Wang, Hong Wu, Jing Liu, Shugeng Cao*, and Qingsong Liu*. Salviachinensines A–F, Antiproliferative Phenolic Derivatives from the Chinese Medicinal Plant Salvia chinensis. J. Nat. Prod. Article Publication Date (Web): October 29, 2018, doi: 10.1021/acs.jnatprod.8b00638
  45. Xuesong Liu#, Beilei Wang#, Cheng Chen#, Zongru Jiang#, Chen Hu, Hong Wu, Yicong Zhang, Xiaochuan Liu, Wenliang Wang, Junjie Wang, Zhenquan Hu, Aoli Wang, Tao Huang, Qingwang Liu, Wei Wang, Li Wang, Wenchao Wang, Tao Ren, Lili Li, Ruixiang Xia, Jian Ge*, Qingsong Liu*, Jing Liu*. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. Eur. J. Med. Chem. 2018, in press doi: 10.1016/j.ejmech.2018.10.007
  46. Beilei Wang#, Jiaxin Wu#, Yun Wu#, Cheng Chen#, Fengming Zou#, Aoli Wang, Hong Wu, Zhenquan Hu, Zongru Jiang, Qingwang Liu, Wei Wang, Yicong Zhang, Feiyang Liu, Ming Zhao, Jie Hu, Tao Hu, Juan Ge, Li Wang, Tao Ren, Yuxin Wang, Jing Liu*, Qingsong Liu*. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor. Eur. J. Med. Chem. 2018, in press. doi: 10.1016/j.ejmech.2018.09.025
  47. Xiaofei Liang#, Feng Li#, Cheng Chen#, Zongru Jiang#, Aoli Wang#, Xiaochuan Liua, Juan Ge, Zhenquan Hu, Kailin Yu, Wenliang Wang, Fengming Zou, Qingwang Liu, Beilei Wang, Li Wang, Shanchun Zhang, Yuxin Wang, Qingsong Liu*, Jing Liu*. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3- methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3- methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kd) inhibitor. Eur. J. Med. Chem. 2018, 156: 831-846. doi: 10.1016/j.ejmech.2018.07.036
  48. Hongbin He#, Hua Jiang, Yun Chen, Jin Ye, Aoli Wang, Chao Wang, Qingsong Liu, Gaolin Liang, Xianming Deng*, Wei Jiang* & Rongbin Zhou*.Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nature Communications. 2018 Jun 29;9(1):2550. doi: 10.1038/s41467-018-04947-6. [Epub ahead of print]
  49. Yu Xue#, Peiran Song#, Zilan Song#, Aoli Wang, Linjiang Tong, Meiyu Geng, Jian Ding, Qingsong Liu , Liping Sun, Hua Xie*, and Ao Zhang*.Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors. J. Med. Chem. 2018 May 9. doi: 10.1021/acs.jmedchem.8b00441. [Epub ahead of print]
  50. Qiang Wang#, Feiyang Liu#, Shuang Qi#, Ziping Qi#, Xiao-E Yan, Beilei Wang, Aoli Wang, Wei Wang, Cheng Chen, Xiaochuan Liu, Zongru Jiang, Zhenquan Hu, Li Wang, Wenchao Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Qingsong Liu*, Jing Liu*.Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia. Eur. J. Med. Chem. 2018 Mar 12;150:366-384. doi: 10.1016/j.ejmech.2018.03.003. [Epub ahead of print]
  51. Kailin Yu# ,Xuesong Liu#, Zongru Jiang#, Chen Hu#, Fengming Zou#, Cheng Chen, Juan Ge, Jiaxin Wu, Xiaochuan Liu, Aoli Wang, Wenliang Wang, Wenchao Wang, Ziping Qi, Beilei Wang, Li Wang, Hezhong Yan, Jiaoxue Wang, Tao Ren, Jun Tang*, Qingsong Liu*, Jing Liu*. Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs). Oncotarget. 2017 Nov 15. doi: 10.18632/oncotarget.22624. [Epub ahead of print]
  52. Hua Jiang#, Hongbin He, Yun Chen, Wei Huang, Jinbo Cheng, Jin Ye, Aoli Wang, Jinhui Tao, Chao Wang, Qingsong Liu, Tengchuan Jin, Wei Jiang, Xianming Deng, Rongbin Zhou*. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017 Oct 11. doi: 10.1084/jem.20171419. [Epub ahead of print]
  53. Aoli Wang#, Xixiang Li#, Cheng Chen#, Hong Wu#, Ziping Qi#, Chen Hu#, Kailin Yu, Jiaxin Wu, Juan Liu, Xiaochuan Liu, Zhenquan Hu, Wei Wang, Wenliang Wang, Wenchao Wang, Li Wang, Beilei Wang, Qingwang Liu, Lili Li, Jian Ge, Tao Ren, Shanchun Zhang, Ruixiang Xia*, Jing Liu*, and Qingsong Liu*. Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d] pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML. J. Med. Chem. 2017 Sep 28. doi: 10.1021/acs.jmedchem.7b00840. [Epub ahead of print]
  54. Yongfei Chen#, Jiaxin Wu#, Aoli Wang#, Ziping Qi#, Taoshan Jiang#, Cheng Chen, Fengming Zou, Chen Hu, Wei Wang, Hong Wu, Zhenquan Hu, Wenchao Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Qingsong Liu*, Jing Liu*. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC. Eur J Med Chem. 2017 Aug 18;139:674-697. doi: 10.1016/j.ejmech.2017.08.035. [Epub ahead of print]
  55. Kwok-Kin Wong, Yan Liu, Yuyang Li, Xiaoen Wang, Feiyang Liu, Peng Gao, Max M. Quinn, Fei Li, Ashley A. Merlino, Cyril H. Benes, Qingsong Liu and Nathanael S. Gray. Gemcitabine and Chk1 inhibitor AZD7762 synergistically suppress the growth of Lkb1-deficient lung adenocarcinoma. Cancer Res. 2017,Jul 28. pii: canres.0567.2017. doi: 10.1158/0008-5472.CAN-17-0567. [Epub ahead of print]
  56. Beilei Wang#, Yuanxin Deng#, Yongfei Chen#, Kailin Yu, Aoli Wang, Qianmao Liang, Wei Wang, Cheng Chen, Hong Wu, Chen Hu, Weili Miao, Wooyoung Hur, Wenchao Wang, Zhenquan Hu, Ellen L. Weisberg, Jinhua Wang, Tao Ren, Yinsheng Wang, Nathanael S. Gray, Qingsong Liu*, Jing Liu*. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors. Eur. J. Med. Chem. 2017,Available online 9 June 2017. doi: 10.1016/j.ejmech.2017.06.016. [Epub ahead of print]
  57. Tao Hu#, Xiaoxue Yuan#, Rongcai Ye#, Huiqiao Zhoua, Jun Lina, Chuanhai Zhang, Hanlin Zhang, Gang Wei, Meng Dong, Yuanyuan Huang, Wonchung Lime, Qingsong Liu, Hyuek Jong Lee*, Wanzhu Jin*. Brown adipose tissue activation by rutin ameliorates polycystic ovary syndrome in rat. J Nutr Biochem. 2017, Apr 22; 47: 21-28. doi: 10.1016/j.jnutbio.2017.04.012. [Epub ahead of print]
  58. Chen Hu#, Aoli Wang#, Hong Wu#, Ziping Qi#, Xixiang Li#, Xiao-E Yan#, Cheng Chen, Kailin Yu, Fengming Zou, Wenchao Wang, Wei Wang, Jiaxin Wu, Juan Liu, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, Qingsong Liu.* Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode. Oncotarget 2017, 8(11): 18359-18372. doi: 10.18632/oncotarget.15443
  59. Zheng Zhao, Qingsong Liu, Spencer Bliven, Lei Xie*, Philip E. Bourne*. Determining cysteines available for covalent inhibition across the human kinome. J. Med. Chem. 2017. doi: 10.1021/acs.jmedchem.6b01815
  60. Hong Wu#, Qiong Huang#, Ziping Qi#, Yongfei Chen#, Aoli Wang, Cheng Chen, Qianmao Liang, Jinghua Wang, Wensheng Chen, Jin Dong, Kailin Yu, Chen Hu, Wenchao Wang, Xiaochuan Liu, Xiaoxiang Li, Nathanael S. Gray, Jing Liu*, Wei Wei*, Qingsong Liu*. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Scientific Reports 2017, doi: 10.1038/s41598-017-00482-4
  61. Aoli Wang#, Xixiang Li#, Hong Wu#, Fengming Zou#, Xiao-E Yan#, Cheng Chen, Chen Hu, Kailin Yu, Wenchao Wang, Peng Zhao, Jiaxin Wu, Ziping Qi, Wei Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, Qingsong Liu*. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy) phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutants Kinase Inhibitor with a Distinct Binding Mode. J. Med. Chem. 2017. 10.1021/acs.jmedchem.6b01907
  62. Juanjuan Liu, Xingxing Yang, Binhua Li, Junjun Wang, Wenchao Wang, Jing Liu, Qingsong Liu, Xin Zhang*. STK16 regulates actin dynamics to control Golgi organization and cell cycle. Scientific Reports 2017, 7: 44607. doi: 10.1038/srep44607.
  63. Qianmao Liang#, Yongfei Chen#, Kailin Yu#, Cheng Chen#, Shouxiang Zhang, Aoli Wang, Wei Wang, Hong Wu, Xiaochuan Liu, Beilei Wang, Li Wang, Zhenquan Hu, Wenchao Wang, Tao Ren, Shanchun Zhang, Qingsong Liu*, Cai-Hong Yun*, Jing Liu*. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor. Eur. J. Med. Chem. 2017, 131: 107-125. doi: 10.1016/j.ejmech.2017.03.001.
  64. Yanke Liang, Melissanne De Wispelaere, Margot Carocci, Qingsong Liu, Jinhua Wang, Priscilla L. Yang*, Nathanael S Gray*. Structure-Activity Relationship study of QL47 - a Broad-spectrum Antiviral agent. ACS Med. Chem. Lett. 2017, 8: 344-349. doi: 10.1021/acsmedchemlett.7b00008.
  65. Xiaofei Liang#, Fengchao Lv#, Beilei Wang#, Kailin Yu#, Hong Wu, Ziping Qi, Zongru Jiang, Cheng Chen, Aoli Wang, Weili Miao, Wenchao Wang, Zhenquan Hu, Juan Liu, Xiaochuan Liu, Zheng Zhao, Li Wang, Shanchun Zhang, Zi Ye, Chu Wang, Tao Ren, Yinsheng Wang, Qingsong Liu*, and Jing Liu*. Discovery of 2-((3-acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. J. Med. Chem. 2017, 60(5):1793-1816. doi:?10.1021/acs.jmedchem.6b01413.
  66. Wu R, Sun JG, Wang JQ, Li B, Qingsong Liu, Ning G, Jin W, Yuan Z*. c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice. Diabetologia 2017, Jan 10. doi: 10.1007/s00125-016-4202-2.
  67. Yifei Yang, Yuan Zhang, LingYun Yang, Leilei Zhao, Lianghui Si, Huibin Zhang, Qingsong Liu, Jinpei Zhou*. Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity. Bioorg. Chem. 2017, 70:126-132. doi: 10.1016/j.bioorg.2016.12.002.
  68. de Wispelaere M, Carocci M, Liang Y, Qingsong Liu, Sun E, Vetter ML, Wang J, Gray NS, Yang PL.Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Res. 2017, 139: 171-179. doi: 10.1016/j.antiviral.2016.12.017.
  69. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Ziping Qi, Cheng Chen, Kailin Yu, Chen Hu, Shuang Qi, Wenchao Wang, Zhenquan Hu, Juan Liu, Wei Wang, Li Wang, Qianmao Liang, Shanchun Zhang, Tao Ren, Qingsong Liu*,Jing Liu*. Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. J. Med. Chem. 2017, 60(1): 273-289. doi: 10.1021/acs.jmedchem.6b01290.
  70. Xiaoxue Yuan#, Gang Wei#, Yilin You#,Yuanyuan Huang, Hyuek Jong Lee,Meng Dong, Jun Lin, Tao Hu, Hanlin Zhang,Chuanhai Zhang, Huiqiao Zhou,Rongcai Ye, Xiaolong Qi, Baiqiang Zhai,Weidong Huang,Shunai Liu,Wen Xie, Qingsong Liu, Xiaomeng Liu,Chengbi Cui,Donghao Li,Jicheng Zhan,Jun Cheng,Zengqiang Yuan, Wanzhu Jin. Rutin ameliorates obesity through brown fat activation. FASEB J. 2017, 31(1): 333-345. doi: 10.1096/fj.201600459RR.
  71. Aoli Wang#, Xiao-E Yan#, Hong Wu#, Wenchao Wang, Chen Hu, Cheng Chen, Zheng Zhao, Peng Zhao, Xixiang Li, Li Wang, Beilei Wang, Zi Ye, Jinhua Wang, Chu Wang, Wei Zhang, Nathanael S. Gray, Ellen L. Weisberg, Liang Chen, Jing Liu*,Cai-Hong Yun*, Qingsong Liu*. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget 2016, 7(43): 69760-69769. doi:?10.18632/oncotarget.11951.
  72. Binhua Li#, Aoli Wang#, Juan Liu#, Ziping Qi#, Xiaochuan Liu#, Kailin Yu, Hong Wu, Cheng Chen, Chen Hu, Wenchao Wang, Jiaxin Wu, Zhenquan Hu, Ling Ye, Fengming Zou, Feiyang Liu, Beilei Wang, Li Wang, Tao Ren, Shaojuan Zhang, Mingfeng Bai, Shanchun Zhang, Jing Liu*, Qingsong Liu*. Discovery of N-((1-(4-(3-(3-((6,7-dimethoxyquinolin-3-yloxy )phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I Gatekeeper Mutant of cKIT Kinase. J. Med. Chem. 2016, 59(18): 8456-72. doi:?10.1021/acs.jmedchem.6b00902.?
  73. Xiaochuan Liu#, Aoli Wang#, Xiaofei Liang#, Juanjuan Liu#, Fengming Zou, Cheng Chen, Zheng Zhao, Yuanxin Deng, Hong Wu, Ziping Qi, Beilei Wan, Li Wang, Feiyang Liu, Yunhe Xu, Wenchao Wang, Stacey M. Fernandes, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, Teckpeng Loh, James. D. Griffin, Shanchun Zhang, Ellen L. Weisberg*, Xin Zhang*, Jing Liu*, Qingsong Liu*.Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies. Oncotarget 2016, 7(33): 53515-53525. doi:? 10.18632/oncotarget.10650.
  74. Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gon?alves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, Heyn H, Deng X, Egan RK, Qingsong Liu, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber DA, Stratton MR, Benes CH, Wessels LF, Saez-Rodriguez J, McDermott U, Garnett MJ. A Landscape of Pharmacogenomic Interactions in Cancer. Cell 2016, 166(3): 740-54. doi: ? 10.1016/j.cell.2016.06.017.
  75. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML). Feiyang Liu#, Beilei Wang#, Qiang Wang#, Ziping Qi#, Cheng Chen#, Lu-Lu Kong#, Ji-Yun Chen, Xiaochuan Liu, Aoli Wang, Chen Hu, Wenchao Wang, Huiping Wang, Fan Wu, Yanjie Ruan, Shuang Qi, Juan Liu, Fengming Zou, Zhenquan Hu, Wei Wang, Li Wang, Shanchun Zhang, Cai-Hong Yun, Zhimin Zhai, Jing Liu*, Qingsong Liu*. Oncotarget 2016, 7(29): 45562-45574. doi: ? 10.18632/oncotarget.10037.
  76. Jihao Wang, Lei Zhang, Chen Hu, Qingsong Liu,Yubin Hou, Xin Zhang, and Qingyou Lu. Sub-molecular features of single proteins in solution resolved with scanning tunneling microscopy. Nano Research 2016, 9(9): 2551-2560. doi: 10.1007/s12274-016-1141-7
  77. Hong Wu#, Aoli Wang#, Ziping Qi#, Xixiang Li#, Cheng Chen#, Kailin Yu, Fengming Zou, Chen Hu, Wenchao Wang, Zheng Zhao, Jiaxin Wu, Juan Liu, Xiaochuan liu, Li Wang, Wei Wang, Shanchun Zhang, Richard M. Stone, Ilene A. Galinsky, James D. Griffin, David Weinstock, Alexandra Christodoulou, Huiping Wang, Yuanyuan Shen, Zhimin Zhai*, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*. Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia 2016, 30: 2112-2116. doi:? 10.1038/leu.2016.151.
  78. Lei Zhang, Jihao Wang, HongLei Wang, Wenchao Wang, Zhiyuan Li, Juanjuan Liu, Xingxing Yang, Xinmiao Ji, Yan Luo, Chen Hu, Yubin Hou, Qianqian He, Jun Fang, Junfeng Wang, Qingsong Liu, Guohui Li, Qingyou Lu, Xin Zhang*. Moderate and strong static magnetic fields directly affect EGFR kinase domain orientation to inhibit cancer cell proliferation. Oncotarget 2016, 7(27): 41527-41539. doi: 10.18632/oncotarget.9479.
  79. Durga Udayakumar, Raj K. Pandita, Nobuo Horikoshi, Yan Liu, Qingsong Liu, Kwok-Kin Wong,Clayton R. Hunt, Nathanael S. Gray, John D. Minna, Tej K. Pandita, and Kenneth D. Westover. Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. Radiat. Res. 2016, 185(5): 527-38. doi: 10.1667/RR14373.1.
  80. Feiyang Liu#, Wang J#, Xingxing Yang#, Binhua Li#, Hong Wu, Shuang Qi, Cheng Chen, Xiaochuan Liu, kailin Yu, Wenchao Wang, Zhao, Aoli Wang, Yongfei Chen, Li Wang, Nathanael S Gray*, Jing Liu*, Xin Zhang*, Qingsong Liu*. Discovery of a Highly Selective STK16 Kinase Inhibitor. ACS Chem. Biol. 2016, 11(6): 1537-1543. doi: 10.1021/acschembio.6b00250.
  81. Shengping Li, Yanhe Zhao, Zheng Zhao, Xiuling Wu, Lifang Sun, Qingsong Liu, Yunkun Wu*. Crystal structure of the GRAS domain of SCARECROW-LIKE 7 in Oryza sativa. Plant Cell 2016, 28: 1025-1034. doi: 10.1105/tpc.16.00018
  82. Zhiyuan Li, Xinmiao Ji, Wenchao Wang, Juanjuan Liu, Xiaofei Liang, Hong Wu, Jing Liu, Ulrike S. Eggert, Qingsong Liu, Xin Zhang*. Ammonia Induces Autophagy through Dopamine Receptor D3 and MTOR. PLoS One 2016, 11(4): e0153526. doi: 10.1371/journal.pone.0153526
  83. Xiaochuan Liu#, Aoli Wang#, Xiaofei Liang#, Cheng Chen#, Juanjuan Liu, Zheng Zhao, Hong Wu, Yuanxin Deng, Wang Li,, Beilei Wang, Jiaxin Wu, Feiyang Liu, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Jennifer R. Brown, James D. Griffin, Shanchun Zhang, Teckpeng Loh, Xin Zhang, Wenchao Wang*, Ellen L. Weisberg* ,Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances., Jing Liu*, Qingsong Liu*. Oncotarget 2016, 7(22): 32641-51. doi:? 10.18632/oncotarget.8702
  84. Aoli Wang#, Hong Wu#, Cheng Chen#, Chen Hu#, Ziping Qi#, Wenchao Wang, Kailin Yu, Xiaochuan Liu, Fengming Zou, Zheng Zhao, Jiaxin Wu, Juan Liu, Feiyang Liu, Wang Li, Richard M. Stone, Ilene A. Galinksy, James D. Griffin4, Shanchun Zhang, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu*. Dual Inhibition of AKT/FLT3-ITD by A674563 Overcomes FLT3 Ligand-Induced Drug Resistance in FLT3-ITD positive AML. Oncotarget 2016, 7(20):29131-42. doi: 10.18632/oncotarget.8675
  85. Qiang Wang#, Feiyang Liu#, Beilei Wang#, Fengming Zou#, Cheng Chen, Xiaochuan Liu, Aoli Wang, Shuang Qi, Wenchao Wang, Ziping Qi, Zheng Zhao, Zhenquan Hu, Wei Wang, Wang Li, Shanchun Zhang, Yuexiang Wang, Jing Liu*, Qingsong Liu *. Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). J. Med. Chem. 2016, 59(8): 3964-79. doi:? 10.1021/acs.jmedchem.6b00200
  86. Xiaoxue Yuan, Tao Hu, Han Zhao, Yuanyuan Huang, Rongcai Ye, Jun Lin, Chuanhai Zhang, Hanlin Zhang, Gang Wei, Huiqiao Zhou, Meng Dong, Jun Zhao, Haibin Wang, Qingsong Liu, Hyuek Jong Lee, Wanzhu Jin, Zi-Jiang Chen. Brown adipose tissue transplantation ameliorates polycystic ovary syndrome. PNAS 2016, 113(10): 2708-13. doi: 10.1073/pnas.1523236113
  87. Xiaofei Liang#, Xiaochuan Liu#, Beilei Wang#, Fengming Zou#, Aoli Wang, Shuang Qi, Cheng Chen, Zheng Zhao, Wenchao Wang, Ziping Qi, Fengchao Lv, Zhenquan Hu, Li Wang, Shanchun Zhang, Qingsong Liu*, Jing Liu*. Discovery of 2-((3-amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a potent, selective and orally available BCR-ABL/SRC/p38 kinase inhibitor for Chronic Myeloid Leukemia. J. Med. Chem. 2016, 59(5): 1984-2004. doi:? 10.1021/acs.jmedchem.5b01618
  88. Yan Luo, Xinmiao Ji, Juanjuan Liu, Zhiyuan Li, Wenchao Wang, Wei Chen, Junfeng Wang, Qingsong Liu, Xin Zhang*. Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and Taxol. Bioelectrochemistry 2016, 109: 31-40. doi: 10.1016/j.bioelechem.2016.01.001
  89. Victor A. Neel, Kristina Todorova, Jun Wang, Eunjeong Kwon, Minjeong Kang, Qingsong Liu, Nathanael Gray, Sam W. Lee, Anna Mandinova. Sustained Akt activity is required to maintain cell viability in seborrheic keratosis, a benign epithelial tumor. Journal of Investigative Dermatology 2016, 136(3): 696-705. doi:? 10.1016/j.jid.2015.12.023
  90. Xixiang Li#, Aoli Wang#, Kailin Yu#, Ziping Qi#, Cheng Chen, Wenchao Wang, Chen Hu, Hong Wu, Jiaxin Wu, Zheng Zhao, Juan Liu, Fengming Zou, Li Wang, Beilei Wang, Wei Wang, Shanchun Zhang, Jing Liu*,Qingsong Liu*. Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. J. Med. Chem. 2015, 58(24): 9625-38. doi: 10.1021/acs.jmedchem.5b01611
  91. Rong Wu, Hong Chen, Jun Ma, Qing He, Qiaoying Huang, Qingsong Liu, mingtao Li, Zengqiang Yuan. c-Abl–p38α signaling plays an important role in MPTP-induced neuronal death. Cell Death & Differentiation 2016, 23(3): 542-52. doi:? 10.1038/cdd.2015.135
  92. Hideki Terai#, Tan Li#, Ellen Monica Beauchamp, John M. Hatcher, Characterization of DDR2 inhibitors for the treatment of DDR2 mutated non-small cell lung cancer. Qingsong Liu, Matthew Meyerson, Nathanael S Gray, and Peter Hammerman. ACS Chem. Biol. 2015, 10(12): 2687-96. doi:? 10.1021/acschembio.5b00655
  93. Hong Wu#, Aoli Wang#, Wei Zhang#, Beilei Wang#, Cheng Chen#,Wenchao Wang, Chen Hu, Zi Ye, Zheng Zhao, Li Wang, Xixiang Li, Kailin Yu,Juan Liu, Jiaxin Wu, Xiao-E Yan, Peng Zhao, Jinhua Wang, Chu Wang,Ellen L. Weisberg, Nathanael S. Gray, Cai-Hong Yun, Jing Liu*, Liang Chen*,Qingsong Liu*. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget 2015, 6(31): 31313-22. 10.18632/oncotarget.5182
  94. Hong Wu#, Chen Hu#, Aoli Wang#, Ellen L. Weisberg#, Yongfei Chen#, Cai-Hong Yun, Wenchao Wang, Yan Liu, Xiaochuan Liu, Bei Tian, Jinhua Wang, Zheng Zhao, Yanke Liang, Binhua Li, Li Wang, Beilei Wang, Cheng Chen, Sara J. Buhrlage, Ziping Qi, Fengming Zou, Atsushi Nonami, Yuyang Li, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Xianhuo Wang, Guang Yang, James D. Griffin, Jennifer R. Brown, Michael J. Eck, Jing Liu*, Nathanael S. Gray*,Qingsong Liu *. Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia. Leukemia 2016, 30(1): 173-81. doi: 10.1038/leu.2015.180
  95. Wu Hong#, Hu Chen#, Wang Aoli#, E L Weisberg#, Wang Wenchao, Chen Cheng, Zhao Zheng, Yu Kailin, Liu Juan, Wu Jiaxin, A Nonami, Wang Li, Wang Beilei, R M Stone, S Liu, J D Griffin,Liu Jing* , Qingsong Liu *. Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia 2016, 30(3):754-7. doi: 10.1038/leu.2015.175
  96. Moccia M, Liu Q , Guida T, Federico G, Brescia A, Zhao Z, Choi HG, Deng X, Tan L, Wang J, Billaud M, Gray NS, Carlomagno F, Santoro M. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase. PLoS One 2015, 10(6): e0128364. doi: 10.1371/journal.pone.0128364
  97. Atsushi Nonami, Martin Sattler, Ellen Weisberg, Qingsong Liu, Jianming Zhang, Matthew P. Patricelli, Amanda L. Christie, Amy M. Saur, Nancy E. Kohl, Andrew L. Kung, Hojong Yoon, Taebo Sim, Nathanael S. Gray, and James D. Griffin. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacological approach. Blood 2015, 125(20): 3133-43. doi: 10.1182/blood-2014-12-615906
  98. Shengyi Peng, Siqi Zhao, Feng Yan, Jinbo Cheng, Li Huang, Hong Chen, Qingsong Liu, Xunming Ji, and Zengqiang Yuan. HDAC2 Selectively Regulates FOXO3a-Mediated Gene Transcription during Oxidative Stress-Induced Neuronal Cell Death. The Journal of Neuroscience 2015, 35(3):1250-1259. doi: 10.1523/JNEUROSCI.2444-14.2015
  99. Chanjuan Wana, Bo Wua, Zhenwei Song, Jiahai Zhang, Huiying Chu, Aoli Wang, Qingsong Liu, Yunyu Shi, Guohui Li, Junfeng Wang. Insights into the molecular recognition of the granuphilin C2A domain with PI(4,5)P2. Chem. Phys. Lipids 2015, 186: 61-7. doi:? 10.1016/j.chemphyslip.2015.01.003
  100. Moore NF1#, Azarova AM#, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS , Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE.Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget 2014, 5(18): 8737-49. doi: 10.18632/oncotarget.2372
  101. Ellen L Weisberg, Atsushi Nonami, Zhao Chen, Erik Nelson, Yongfei Chen, Feiyang Liu, Haeyeon Cho, Jianming Zhang, Martin Sattler, Constantine S. Mitsiades, Kwok-Kin Wong, Qingsong Liu, Nathanael S. Gray, James D Griffin. Up-regulation of IGF-1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small molecule inhibition of IGF-1R. Clin. Cancer Res. 2014, 20(21): 5483-95. doi: 10.1158/1078-0432.CCR-14-0902
  102. Ellen Weisberg#,Atsushi Nonami#, Zhao Chen, Feiyang Liu, Jianming Zhang, Martin Sattler, Erik Nelson, Kristen Cowens, Amanda Christie, Constantine Mitsiades, Kwok-Kin Wong, Qingsong Liu, Nathanael Gray, James Griffin*. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia, 2015,Jan;29(1):27-37. doi:10.1038/leu.2014.149. 10.1021/acs.jmedchem.5b01618
  103. Zheng Zhao, Hong Wu, Li Wang, Yi Liu, Stefan Knapp, Qingsong Liu*, Nathanael S. Gray*. Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? ACS Chem. Biol. 2014, 9(6): 1230-41. doi:??? 10.1021/cb500129t
  104. Codeluppi S, Fernandez Zafra T, Kjell J, Sandor K, Liu Q , Abrams M, Olson L, Gray NS, Svensson CI, Uhlén P. Interleukin-6 secretion by astrocytes is dynamically regulated by PI3K-mTOR-calcium signaling. PloS ONE 2014, 9(3): e92649. doi: 10.1371/journal.pone.0092649
  105. Hong Wu#, Wenchao Wang#, Feiyang Liu#, Ellen E. Weisberg#, Bei Tian, Yongfei Chen, Binhua Li, Aoli Wang , Beilei Wang, Zheng Zhao, Douglas W. McMillin, Chen Hu, Hong Li, Jinhua Wang, Yanke Liang, Sara J. Buhrlage, Junting Liang, Jing Liu, Guang Yang, Jennifer R. Brown, Steven P. Treon, Constantine S. Mitsiades, James Griffin, Qingsong Liu*, Nathanael S. Gray*. Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma. ACS Chem. Biol. 2014, 9(5):1086-91.doi: 10.1021/cb4008524
  106. Kim HG#, Tan L, Weisberg EL#, Liu F#, Canning P#, Choi HG#, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q *, Lee SW*, Gray NS*. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem. Biol. 2013, 8(10): 2145-50. doi: ? 10.1021/cb400430t
  107. Feiyang Liu#, Xin Zhang#, Ellen Weisberg#, Sen Chen#, Wooyoung Hur, Hong Wu, Zheng Zhao, Wenchao Wang, Mao Mao, Changmeng Cai, Nicholas I. Simon, Takaomi Sanda, Jinhua Wang, A. Thomas Look, James D. Griffin, Steve Balk*, Qingsong Liu*, Nathanael S. Gray*. Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem. Biol. 2013, 8(7): 1423-8. doi: ? 10.1021/cb4000629
  108. Liu Y, Marks K, Cowley GS, Carretero J, Liu Q , Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov. 2013, 3(8): 870-9. doi: 10.1158/2159-8290
  109. Mikko Taipale, Irina Krykbaeva, Luke Whitesell, Sandro Santagata, Jianming Zhang, Qingsong Liu, Nathanael S. Gray, and Susan Lindquist*. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nature Biotechnology 2013, 31(7): 630-7. doi: 10.1038/nbt.2620
  110. Frederico S.L.M. Rodrigues#,Xueyan Yang# , Masataka Nikaido ,Qingsong Liu, Robert N Kelsh*. A simple, highly visual in vivo screen for anaplastic lymphoma kinase inhibitors. ACS Chem. Biol. 2012, 7(12): 1968-74. doi: 10.1021/cb300361a
  111. Giubellino A*, Bullova P, N?lting S, Turkova H, Powers JF, Liu Q , Guichard S, Tischler AS, Grossman AB, Pacak K*. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology 2013, 154(2): 646-55. doi: 10.1210/en.2012-1854
  112. Ellen Weisberg*,Qingsong Liu*, Xin Zhang, Erik Nelson, Martin Sattler, Feiyang Liu, Maria Nicolais, Jianming Zhang, Constantine Mitsiades, Robert Smith, Richard Stone, Ilene Galinsky, Atsushi Nonami, James D. Griffin, and Nathanael Gray. Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLOS ONE 2013, 8(2): e56473. doi: ? 10.1371/journal.pone.0056473
  113. Rachel G. Liao, Joonil Jung, Matthew D. Wilkerson, Andrey Sivachenko, Qingsong Liu ,Trevor J. Pugh,Chandra Sekhar Pedamallu, D. Neil Hayes, Nathanael S. Gray, Gad Getz, Robert I. Haddad, Matthew Meyerson*. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Research 2013, 73(16): 5195-205.? 10.1158/0008-5472.CAN-12-3950
  114. Ruchi Jain, Deepak Jain, Qingsong Liu, Desiree Schumann, Peter Eickelmann, Lorenzo Piemonti, Nathanael S. Gray, Eckhard Lammert.* Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets. Diabetologia 2013, 56(6): 1350-5. doi: ? 10.1007/s00125-013-2877-1
  115. Azab AK#, Weisberg E#, Sahin I, Liu Feiyang, Awwad R, Azab F, Qingsong Liu, Griffin JD, Ghobrial IM. The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression. Leukemia 2013, 27(4): 961-4. doi: ? 10.1038/leu.2012.353
  116. Jing Liu, Feiyang Liu, David L. Waller, Junfeng Wang, Qingsong Liu*. Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies. Current Angiogenesis 2012, 1(4): 335-346. doi: 10.2174/2211552811201040335
  117. Qingsong Liu, Lyn H. Jones, Yogesh Sabnis, Zheng Zhao, Tinghu Zhang, Nathanael S. Gray*. Developing irreversible inhibitors of the protein kinase cysteinome. Chemistry & Biology, 2013, 20(2): 146-59. doi: 10.1016/j.chembiol.2012.12.006
  118. Teeara Berry, William Luther, Yann Jamin1, Namrata Bhatnagar,, Winston A. Vetharoy, Takaomi Sanda, Christina Sch?nherr, Bandana Sharma , Albert Hallsworth, Karen Barker, Zahida Ahmad, Dorine Bax, Hannah Webber, Lisa Moreau, Qingsong Liu, Lynsey Vaughan, Wenchao Wang, Andrew Pearson, Antonio Perez-Atayde, Bengt Hallberg, Scott Rodig, Chris Jones, Simon Robinson, Nathanael Gray, Suzanne A. Eccles, Louis Chesler*, Rani E. George*. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 2012, 22(1): 117-30. doi: 10.1016/j.ccr.2012.06.001
  119. Qingsong Liu#, Chunxiao Xu# ,Sivapriya Kirubakaran, Xin Zhang, Wooyoung Hur, Yan Liu, Nicholas P. Kwaitkowski, Jinhua Wang, Kenneth Westover, Peng Gao, Dalian Erica,? Carson C. Thoreen, Seong A. Kang, Matthew P. Patricelli, Pasi A. Janne, Kwok Wong, David M.Sabatini, Nathanael S. Gray*. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Research 2013, 73(8): 2574-2586. doi: 10.1158/0008-5472.CAN-12-1702
  120. Ellen Weisberg#,Qingsong Liu#, Erik Nelson, Andrew L. Kung, Amanda L. Christie, Rod Bronson, Martin Sattler, Takaomi Sanda, Zheng Zhao, Wooyoung Hur, Constantine Mitsiades, Robert Smith, John F. Daley, Richard Stone, Ilene Galinsky, James D. Griffin, Nathanael Gray*. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia 2012, 26(10): 2233-44. doi: 10.1038/leu.2012.96
  121. Jing Ni#,Qingsong Liu#, Shaozhen Xie, Coby Carlson, Thanh Von, Kurt W. Vogel, Steve M. Riddle, Cyril H. Benes, Michael Eck, Thomas M. Roberts, Nathanael S. Gray,* Jean J. Zhao*.Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discovery 2012, 2(5): 425-33. doi: 10.1158/2159-8290.CD-12-0003
  122. Qingsong Liu#, Tao Ren#, Tara Fresques#, Wolfgang Oppliger, Brad J. Niles, Wooyoung Hur, David Sabatini, Michael N. Hall, Ted Powers, Nathanael S. Gray*. Selective ATP-competitive inhibitors of TOR suppress rapamycin-insensitive function of TORC2 in Saccharomyces cerevisiae. ACS Chem. Biol. 2012, 7(6): 982-7. doi: 10.1021/cb300058v
  123. Mathew J. Garnett#, Elena E. Edelman#, Sonja J. Heidorn#, Chris Greenman, Anahita Dastur, Ian Richard Thompson, Pat Greninger, Jorge Soares, Xi N. Luo, King Wai Lau, Qingsong Liu, Francesco Lorio, Randy J. Milano, Graham Bignell, Ah T. Tam, Helen Davies, Jesse A. Stevenson, Andrew Barthorpe, Stephen R. Lutz, Anne McLaren-Douglas, Xeni Mitropoulos, Tatiana Mironenko, Helen Thi, Laura Richardson, Wenjun Zhou, Frances Jewitt, Tinghu Zhang, Patrick O’Brien, Wooyoung Hur, Wanjuan Yang, Xianming Deng, Adam Butler, Hwan Geun Choi, Jae Won Chang, Jose Baselga, Ivan Stamenkovic, Jeffrey A. Engelman, Sreenath V. Sharma, Julio Saez-Rodriguez, Nathanael S. Gray, Jeffrey Settleman, P. Andrew Futreal, Daniel A. Haber, Michael R. Stratton, Sridhar Ramaswamy, Ultan McDermott*, Cyril H. Benes*.Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483(7391): 570-5. doi: 10.1038/nature11005
  124. Qingsong Liu, Sivapriya Kirubakaran, Wooyoung Hur, Mario Niepel, Kenneth Westover, Carson C. Thoreen, Jinhua Wang, Jing Ni, Matthew P. Patricelli, Kurt Vogel, Steve Riddle, David L. Waller, Ryan Traynor, Takaomi Sanda, Seong A. Kang, Jean, Zhao, A. Thomas Look, Peter K. Sorger, David M. Sabatini, Nathanael S. Gray*.Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. J. Bio. Chem. 2012, 287(13): 9742-52. doi: 10.1074/jbc.M111.304485
  125. Jing Liu, Yi Hu, David L. Waller, Junfeng Wang, Qingsong Liu*. Natural products as kinase inhibitors. Natural Products Reports 2012, 29(3): 392-403. doi: 10.1039/c2np00097k
  126. Priscilla L Yang. Min Gao; Kai Lin, Qingsong Liu, Valerie A Villareal*. Anti-HCV drugs in the pipeline. Curr. Opin. Virol. 2011, 1(6): 607-16. doi: 10.1016/j.coviro.2011.10.019
  127. Yi Hu, Jing Liu, Junfeng Wang, Qingsong Liu*. The controversial links among calorie restriction, SIRT1, and resveratrol. Free Radic. Biol. Med. 2011, 51(2): 250-6. doi: 10.1016/j.freeradbiomed.2011.04.034
  128. Ilona Obara, Keri K. Tochiki, Sandrine M. Géranton, Fiona B. Carr, Bridget M. Lumbc, Qingsong Liu, Stephen P. Hunt*. Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice. Pain?2011, 152(11): 2582-95. doi: ? 10.1016/j.pain.2011.07.025
  129. Xianming Deng, Nicolas Dzamko, Alan Prescott, Paul Davies, Qingsong Liu, Qingkai Yang, Jiing-Dwan Lee, Matthew P. Patricelli, Tyzoon K. Nomanbhoy, Dario R. Alessi, and Nathanael S. Gray*. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chem. Biol. 2011, 7(4): 203–205. doi: 10.1038/nchembio.538
  130. Qingsong Liu, jinhua Wang, Seong A. Kang, Carson, C. Thoreen, wooyoung Hur, David Sabatini,Nathanael Gray*,Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability. Bioorg. Med. Chem. Lett. 2011, 21(13):4036-40. doi: 10.1016/j.bmcl.2011.04.129
  131. Qingsong Liu, Jinhua Wang, Seong A. Kang, Carson, C. Thoreen, David Sabatini, Nathanael Gray*. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. J. Med. Chem. 2011, 21(13): 4036-40. doi: 10.1021/jm101520v
  132. Qingsong Liu, Jinhua Wang, Seong A. Kang, Carson, C. Thoreen, David Sabatini, Nathanael Gray*.Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J. Med. Chem. 2010, 53(19): 7146-55. doi: 10.1021/jm101144f
  133. Qingsong Liu, Thoreen C, Wang J, Sabatini D, Gray NS. mTOR Mediated Anti-Cancer Drug Discovery. Drug Discov. Today Ther. Strateg. 2009, 6(2): 47-55.doi: 10.1016/j.ddstr.2009.12.001
  134. Weisberg E1*, Barrett R, Liu Q , Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resistance Updates 2009, 12(3): 81-9. doi: 10.1016/j.drup.2009.04.001
  135. Choi Y1, Syeda F, Walker JR, Finerty PJ Jr, Cuerrier D, Wojciechowski A, Liu Q , Nathanael Gray*. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Dhe-Paganon S, Gray NS. Bioorg. Med. Chem. Lett. 2009, 19: 4467-4470. doi: 10.1016/j.bmcl.2009.05.029
  136. Thoreen CC, Kang SA, Chang JW, Liu Q , Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS*. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284(12): 8023–8032.?doi:? 10.1074/jbc.M900301200
  137. Ghidu VP, Wang J, Wu B, Liu Q , Jacobs A, Marnett LJ, Sulikowski GA*.Synthesis and evaluation of the cytotoxicity of apoptolidinones A and D. J. Org. Chem. 2008, 73(13): 4949-55. doi: 10.1021/jo800545r
  138. Bin Wu, Qingsong Liu, Tao Qu and Gary A. Sulikowski.E*. Studies on the Synthesis of Apoptolidin: Progress on the Stereocontrolled Assembly of the Pseudo Aglycone of Apoptolidin. Eur. J. Org. Chem. 2006, 2006: 277-284.? 10.1002/ejoc.200500632
  139. Bohan Jin, Qingsong Liu, G. A. Sulikowski*. Development of an End-Game Strategy Towards Apoptolidin: a Sequential Suzuki Coupling Approach. Tetrahedron 2005, 61: 401-408. 10.1016/j.tet.2004.10.088
  140. Bin Wu, Qingsong Liu, Gary, A. Sulikowski*, Total Synthesis of Apoptolidinone. Angew. Chem. Int. Ed. 2004, 43: 6673-6675. doi: 110.1002/anie.200461469